This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Coeptis Therapeutics Management
Management criteria checks 1/4
Key information
Dave Mehalick
Chief executive officer
US$216.5k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 1.6yrs |
| CEO ownership | 3.5% |
| Management average tenure | no data |
| Board average tenure | 1.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$217k | US$217k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$149k | US$149k | -US$9m |
| Dec 31 2019 | US$147k | US$147k | -US$2m |
Compensation vs Market: Dave's total compensation ($USD216.50K) is below average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.
CEO
Dave Mehalick (53 yo)
1.6yrs
Tenure
US$216,500
Compensation
Mr. David Mehalick, also known as Dave, is Chief Business Officer at Sparta Healthcare Acquisition Corp. He is a co-founder of Coeptis Therapeutics Inc. (formerly known as Vinings Holdings Inc.) (formerly...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.6yrs | US$216.50k | 3.52% $ 6.0m | |
| Co-Founder | 1.6yrs | US$133.50k | 5.86% $ 10.1m | |
| Co-Founder | 1.6yrs | US$205.50k | 5.86% $ 10.1m | |
| Member of Scientific and Clinical Advisory Board | less than a year | no data | no data | |
| Member of Scientific and Clinical Advisory Board | less than a year | no data | no data | |
| Member of Scientific and Clinical Advisory Board | less than a year | no data | no data |
1.2yrs
Average Tenure
53yo
Average Age
Experienced Board: COEP's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.